Progyny, Inc. PGNY
Nasdaq · XNAS · stock · Services-Misc Health & Allied Services, NEC
Chart by TradingView
5/9
Piotroski F — financial health
7.14
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.3B | $58.5M | $304.5M | $191.8M | $516.0M |
| 2024 | $1.2B | $54.3M | $253.4M | $173.7M | $422.1M |
| 2023 | $1.1B | $62.0M | $238.8M | $185.2M | $553.4M |
| 2022 | $786.9M | $30.4M | $167.3M | $77.2M | $377.0M |
| 2021 | $500.6M | $65.8M | $112.1M | $23.9M | $251.8M |
| 2020 | $344.9M | $46.5M | $70.1M | $35.2M | $166.9M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.14 (safe)
- Working capital / assets 0.471
- Retained earnings / assets 0.273
- EBIT / assets 0.115
- Equity / liabilities 2.279
Source: SEC EDGAR filings · CIK 0001551306 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.